Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
 |
U.S. Department of Health and Human Services; National Institutes Of Health; NIH News; National Institute of Allergy and Infectious Diseases (NIAID) - Wednesday, June 25, 2008
CONTACT: Laura Sivitz, 301-402-1663, e-mail:sivitzl@niaid.nih.gov
To accelerate the translation of basic discoveries about HIV into advances in vaccine design and evaluation, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has formed a new Vaccine Discovery Branch within the Vaccine Research Program in the Division of AIDS (DAIDS).
"There is broad scientific consensus that designing a safe and effective vaccine to prevent HIV infection will require enormous advances beyond present-day knowledge," says NIAID Director Anthony S. Fauci, M.D. "The NIAID Vaccine Discovery Branch will help remove fundamental obstacles to achieving this goal by focusing intensively on the development and sharing of new knowledge critical to vaccine development."
The new branch is dedicated to monitoring scientific developments in multiple fields related to HIV vaccine discovery, building more bridges between basic researchers and HIV vaccine designers, identifying gaps in knowledge pertinent to a preventive HIV vaccine and promoting research to fill those gaps.
"Cross-fertilization of HIV/AIDS research with the fields of genetics, structural biology, systems biology and others could open up new perspectives on how to overcome major obstacles to HIV vaccine design," says DAIDS Director Carl W. Dieffenbach, Ph.D. "The Vaccine Discovery Branch will be in an ideal position to spot these opportunities, promote the translation of new knowledge about HIV and foster fruitful research collaborations."
In addition, the new branch will:
The Vaccine Discovery Branch also will have chief oversight of the Center for HIV/AIDS Vaccine Immunology (CHAVI), a consortium of universities and academic medical centers established by NIAID to solve major problems in HIV vaccine development and design. A multidisciplinary group of scientists from across DAIDS will continue to participate in overseeing CHAVI.
Jorge Flores, M.D., deputy director of the Vaccine Research Program, will serve as acting chief of the new branch until a national search results in the selection of a new chief. Dr. Flores has been involved in the conduct and administration of vaccine research at NIH since 1979.
Information about HIV/AIDS prevention, treatment and clinical trials is available at http://www.aidsinfo.nih.gov/.
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at <http://www.niaid.nih.gov>.
The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
080625
NI080601
Published 2008 - National Institute of Allergy and Infectious Diseases . All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .